The Current State of Targeted Therapy in Melanoma: This Time It's Personal
- 1 April 2012
- journal article
- review article
- Published by Elsevier BV in Seminars in Oncology
- Vol. 39 (2), 204-214
- https://doi.org/10.1053/j.seminoncol.2012.01.008
Abstract
No abstract availableThis publication has 110 references indexed in Scilit:
- Acquired Resistance to BRAF Inhibitors Mediated by a RAF Kinase Switch in Melanoma Can Be Overcome by Cotargeting MEK and IGF-1R/PI3KCancer Cell, 2010
- Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanomaNature, 2010
- Using genetics and genomics strategies to personalize therapy for cancer: Focus on melanomaBiochemical Pharmacology, 2010
- RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAFNature, 2010
- Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAFCell, 2010
- AP24534, a Pan-BCR-ABL Inhibitor for Chronic Myeloid Leukemia, Potently Inhibits the T315I Mutant and Overcomes Mutation-Based ResistanceCancer Cell, 2009
- BRAF mutation predicts sensitivity to MEK inhibitionNature, 2005
- Dynamics of chronic myeloid leukaemiaNature, 2005
- Targeted cancer therapyNature, 2004
- Mutations of the BRAF gene in human cancerNature, 2002